Development of anti-atherosclerotic tissue-engineered blood vessel by A20-regulated endothelial progenitor cells seeding decellularized vascular matrix
Development of anti-atherosclerotic tissue-engineered blood vessel by A20-regulated endothelial progenitor cells seeding decellularized vascular matrix
复制标题
通过 A20 调节的内皮祖细胞接种脱细胞血管基质开发抗动脉粥样硬化组织工程血管。
DOI：
10.1016/j.biomaterials.2008.03.005
复制
发表时间：
2008-06-01
期刊：
影响因子：
14
通讯作者：
Zhang, Wei
中科院分区：
文献类型：
--
作者：
Zhu, Chuhong;Ying, Dajun;Zhang, Wei
探讨脱细胞血管组织和A20调控的内皮祖细胞能否用于构建具有抗动脉粥样硬化血管狭窄特性的转基因组织工程血管。A20基因转染的内皮祖细胞在生物反应器中分化为内皮细胞和平滑肌细胞，并附着和迁移到脱细胞猪血管支架中。导管的组织学显示有活力的分层组织。扫描电子显微镜显示融合，均匀的组织表面。脉冲结构的机械强度与人体动脉的机械强度相似。在体内，将A20基因转染的组织工程血管移植到大鼠颈动脉中6个月。血管异种移植引起超急性排斥反应;所有移植的对照血管均完全排斥，但A20转染的组织工程血管在植入时表现出良好的流动性，并在术后6个月保持开放，如多普勒所评估的。HE染色显示血管通畅，6个月后无狭窄或扩张迹象。这些结果表明，转基因组织工程血管具有长期通畅性和独特的抗狭窄特性。(c)2008爱思唯尔有限公司保留所有权利。
To investigate whether decellularized vascular tissues and A20-regulated endothelial progenitor cells can be used for constructing a transgenic tissue-engineered blood vessel with anti-atherosclerotic vascular stenotic properties. A20 gene-transfected endothelial progenitor cells differentiated endothelial cells and smooth muscle cells attached to and migrated into the decellularized porcine vascular scaffolding in a bioreactor. The histology of the conduits revealed viable and layered tissue. Scanning electron microscopy showed confluent, homogeneous tissue surfaces. The mechanical strength of the pulsed constructs was similar to that of the human artery. In vivo, the A20 gene-transfected tissue-engineered blood vessels were transplanted into the carotid artery of a rat for 6 months. Blood vessel xenotransplantation caused hyperacute rejection; all transplanted control blood vessels were completely rejected, but A20-transfected tissue-engineered blood vessels demonstrated good flow on implantation, and remained open for 6 months postoperatively, as assessed by Doppler. The HE stain demonstrated that the vessels were patent, without evidence of stenosis or dilatation after 6 months. These results demonstrate that transgenic tissue-engineered blood vessels have long-term patency and unique anti-stenotic properties. (c) 2008 Elsevier Ltd. All rights reserved.